Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 71.7% in January

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant decrease in short interest in January. As of January 15th, there was short interest totaling 16,265 shares, a decrease of 71.7% from the December 31st total of 57,446 shares. Approximately 0.9% of the shares of the stock are sold short. Based on an average daily trading volume, of 106,459 shares, the days-to-cover ratio is presently 0.2 days. Based on an average daily trading volume, of 106,459 shares, the days-to-cover ratio is presently 0.2 days. Approximately 0.9% of the shares of the stock are sold short.

Bluejay Diagnostics Price Performance

NASDAQ BJDX opened at $0.76 on Wednesday. The business has a fifty day moving average price of $0.92 and a two-hundred day moving average price of $1.45. The stock has a market capitalization of $1.38 million, a PE ratio of -0.01 and a beta of 0.65. Bluejay Diagnostics has a fifty-two week low of $0.63 and a fifty-two week high of $10.20.

Bluejay Diagnostics shares are going to reverse split on Thursday, January 29th. The 1-4 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Wednesday, January 28th.

Bluejay Diagnostics (NASDAQ:BJDX) last announced its quarterly earnings data on Friday, November 7th. The company reported ($1.01) earnings per share for the quarter.

Analyst Ratings Changes

BJDX has been the subject of several analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Bluejay Diagnostics in a report on Monday, December 29th. Wall Street Zen raised Bluejay Diagnostics to a “sell” rating in a research note on Saturday, November 1st. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc (NASDAQ: BJDX) is a molecular diagnostics company focused on developing saliva-based tests for autoimmune and gastrointestinal conditions. The company’s lead diagnostic product is designed to detect tissue transglutaminase (tTG) antibodies in patient saliva samples, offering a noninvasive, point-of-care alternative to traditional blood draws and endoscopic procedures.

Leveraging a proprietary immunoassay platform, Bluejay’s technology aims to streamline the detection and monitoring of celiac disease by providing rapid results outside of a conventional laboratory setting.